14 studies found for:    Lu-31-130
Show Display Options
Rank Status Study
1 Completed Efficacy of Lu 31-130 in Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Zicronapine;   Drug: Placebo
2 Completed Efficacy of Lu 31-130 in Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Zicronapine;   Drug: Olanzapine
3 Completed Safety and Efficacy of Zicronapine in Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Zicronapine;   Drug: Risperidone
4 Completed Study of the Safety, Tolerability and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Zicronapine
5 Completed This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID;   Drug: Enalapril 10 mg BID
6 Active, not recruiting Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure
Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy;   Drug: Aliskiren monotherapy;   Drug: Aliskiren / Enalapril combination therapy
7 Recruiting Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
8 Completed A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
9 Recruiting Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Condition: Chronic Heart Failure With Reduced Ejection Fraction.
Intervention: Drug: LCZ696
10 Recruiting Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Condition: Atherosclerosis
Interventions: Drug: Canakinumab;   Drug: Placebo
11 Recruiting Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
Condition: COPD
Interventions: Drug: Glycopyrronium;   Drug: SABA;   Drug: LABA;   Drug: Indacaterol maleate and glycopyrronium bromide;   Drug: LAMA;   Drug: SAMA;   Drug: ICS
12 Completed
Has Results
Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan
Condition: Hypertension
Intervention:
13 Completed Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)
Condition: Parkinson's Disease
Interventions: Drug: PYM50028;   Drug: Placebo
14 Completed
Has Results
Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment
Condition: Atrial Fibrillation
Intervention:

Indicates status has not been verified in more than two years